Analisis Cost Effectiveness Penggunaan Antidiabetes Berdasarkan Paket Ina-Cbgs Pada Pasien Diabetes Mellitus Tipe I Rawat Inap Di Rumah Sakit Umum Pusat Haji Adam Malik Medan

American Diabetes Association. (2012). Position Statement: Standards of Medical
Care in Diabetes 2012. Diabetes Care, 33 (Suppl.1). http://care.diabetesjournals.org.
American Diabetes Association. (2015). Standards of Medical Care in Diabetes2015. Diabetes Care. 38 (1): S1-S4
Anonim. (2008). Kepentingan Farmakoekonomi. http://www.cintalestariwordpress.com.
Anonim. (2013). Jumlah Penderita Diabetes Melitus Menurut WHO 2013.
http://www.healthylifeindonesia.com.
Berger, M. L., dkk. (2003). Health Care Cost, Quality, and Outcomes : ISPOR
Book of Terms. ISPOR. USA.
Bootman, J. L. (2005). Principles of Pharmacoeconomics. 3rd Edition. Harvey
Whitney Books Company. USA.
Cheng, A., Zinman, B. dan Khan, C. R. (2005). Joslin’s Diabetes Mellitus. Fourth
Edition. Lipincott Williams & Wilkins. Philadelphia.
Ditjen Bina Farmasi dan Alkes. (2005). Pharmaceutical Care Untuk Penyakit
Diabetes Mellitus. Jakarta. Halaman: 7-47.
Drummond, M. F. (1999). An Intriduction to Health Ecomonics. Brookwood
Medical Publications: 46.
Emily, L. (2005). Guidelines for Adolescent Nutrition Services. Chapter 14.
Diabetes Mellitis: Type 1 and Type 2. Indianapolis: Franklin Publishing
Incorporated. Halaman: 169-170.
Esti, P., Prihwanto, B. S., Wiranto., Diana, H. dan Fifteen, A. F. (2012). Analisis
Efektivitas Biaya Berdasarkan Nilai ACER Penggunaan Insulin

Dibandingkan Kombinasi Insulin-Metformin pada Pasien Diabetes
Melitus Tipe 2 di Instalasi Rawat Inap RSD dr.Soebandi Jember Periode
2012. Artikel Ilmiah Hasil Penelitian Mahasiswa 2012. Fakultas Farmasi
Universitas Jember.
Hirsch, I. B. (2005). Insulin Analog. England: J Med. Halaman: 174-183.
Indrawaty, S. (2013). Pedoman Penerapan Kajian Farmakoekonomi. Jakarta:
Kementerian Kesehatan RI. Halaman: 15-16.
International Diabetes Federation. (2012). Diabetes Atlas 5th Edition. IDF.
Belgium.

53

International Diabetes Federation. (2013). IDF Diabetes Atlas. Sixth Edition.
www.idf.org/diabetesatlas.
Irawan, D. (2010). Prevalensi dan Faktor Risiko Kejadian Diabetes Melitus Tipe
2 di Daerah Urban Indonesia (Analisa Data Sekunder Riskesdas 2007).
Thesis Universitas Indonesia.
Kee, J. L. dan Hayes, E. R. (1996). Farmakologi: Pendekatan Proses keperawatan.Jakarta: EGC. Halaman: 593.
Manan, H. S. (2011). Reference Guide for Pharmacy Management and Pharmaco
economics. Second Edition. National Association of Boards of Pharmacy.

Halaman: 53.
Nathan, D. M., dkk. (2006). Management of Hyperglycemia in Type 2 Diabetes: A
Consensus Algorithm for The Initiation and Adjustment of Therapy A
Consensus Statement From The American Diabetes Association and The
European Association for The Study of Diabetes. Diabetes Care. 29: 19631972.
National Institute of Diabetes, Digestive and Kidney Diseases. (2013). Your
Guide to Diabetes: Type 1 and Type 2. Department of Health and Human
Service. USA.
Newby, D. dan Hill, S. (2003). Use of Pharmacoeconomics in Prescribing
Research. Part 2: Cost-Minimization Analysis-When Are Two Therapies
Equal. Journal of Clinical Pharmacy and Therapeutics. 28:145-148.
Perkeni. (2011). Konsensus Pengelolaan dan Pencegahan Diabetes Melitus Tipe
2 di Indonesia. Perkeni. Jakarta.
PerMenkes, RI. (2014). Petunjuk Teknis Sistem Indonesian Case Base Groups
(INA-CBGs). Jakarta.
PerMenkes, RI. (2014). Standar Paket Pelayanan Kesehatan
Penyelenggaraan Program Jaminan Kesehatan. Jakarta.

Dalam

Rascati, K. I., Drmmond, M. F., Annemans, I. dan Davey, P.G. (2004). Education
in Pharmacoeconomies: an Internasional Multidiciplinary View (Review).
Pharmaco-Economics 2004.
Robertson, D. dan Gordon, H. W. (2009). Pharmacoeconomics: The Economic
Evalution of New Medical Thecnology. Chapter 34. Clinicla and Trans
lation Science. Elsevier. Halaman: 519.
Rudy, B. Dan Richard, D. (2010). Handbook of Diabetes. Fourth Edition .A John
Wiley & Sons: Blackwell Publishing. Halaman: 29.

54

Schulman, K. A., Glick, H.dan Polsky, D. et al. (2000). Pharmacoeconomics:
Economics evaluation of pharmaceuticals. 573-601. In Strom BL (eds).
Pharmacoepidemiology. John Wileuy.
Soegondo S. (1995). Diagnosis dan Klasifikasi Diabetes Melitus Terkini. Dalam
Buku Penatalaksanaan Diabetes Melitus.
Sterling, J. C. (2004). Virus Infections. Dalam Buku Rook’s Textbook of Dermatology. Edisi VII. Massachusetts: Blackwell Publishing.
Suherman. S. K. (2007). Insulin dan Antidiabetes Oral. Dalam Buku Farmakologi
Bdan Terapi Edisi V. Jakarta: FK UI. Halaman 485.
Suryadi, R. M. (2007). Risiko Penyakit Diabetes Melitus Tipe 2 di Kalangan

Peminum Kopi di Kotamadya Palembang Tahun 2006-2007.Makara
Kesehatan. 11(2): 54-60.
Tjiptoherijanto P. dan Soesetyo, B. (1994). Ekonomi Kesehatan. Penerbit Renika
Cipta. Jakarta.
Vogenberg, F. R. (2001). Introduction to Applied Pharmacoeconomics. McGraw
Hill Medical Publishing Division, USA.
Wahyuni, N. K. E., Larasanthy, L. P. F. dan Udayani N. N. W. (2012). Analisis
Efektivitas Biaya Penggunaan Terapi Kombinasi Insulin dan OHO Pada
Pasien Diabetes Melitus Tipe 2 Rawat Jalan di RSUD Wangaya. Jurusan
Farmasi Fakultas Matematika dan Ilmu Pengetahuan Alam Universitas
Udayana. Jimbaran-Bali. Indonesia.
Walley, T. dan Alan, H. (2004). Pharmacoeconomics. Churchill Livingstone.
Spain.
Wilson, D. D. (2008). Manual of Laboratory &Diagnostic Tests. New York: McGrawhill Coampanies, Inc. Halaman: 288.
World Health Organization. (1999). Definition, Diagnosis and Classification of
Diabetes Mellitus and its Complications. Part 1: Diagnosis
andClassification of Diabetes Mellitus. Department of Noncommunicable
Disease Surveillance. Geneva.

55